At the heart of his argument is profound skepticism toward the federal institutions now positioning themselves as guardians of these potent tools. Malone invokes the long-running controversy over U.S.-funded gain-of-function research—tracing taxpayer money through the NIH, EcoHealth Alliance, and foreign laboratories such as the Wuhan Institute of Virology—to assert that the same agencies demanding public trust have historically funded, defended, and obscured risky biological programs. He emphasizes that uncovering basic facts about this research required years of congressional inquiries, subpoenas, litigation, whistleblowers, and relentless public pressure, painting a picture of a bureaucracy structurally resistant to transparency and meaningful accountability.
Malone further contends that Congress has demonstrated an ability to investigate but a repeated failure to govern effectively. Despite hearings, reports, sharply worded letters, and public confrontations, he observes that the fundamental architecture of biodefense funding and grant-making remains largely intact. Operational competence is also sharply questioned; Malone cites recent federal charges against NIH researchers allegedly smuggling mpox and other biological materials into the United States as evidence that these institutions cannot reliably control existing pathogens, let alone oversee advanced AI systems capable of dramatically accelerating viral engineering or experimental design.
The critique broadens to the international arena, where Malone suggests the U.S. government has effectively “offshored” dual-use biological research through an opaque network of foreign laboratories and international partnerships, sometimes situated in geopolitically volatile regions. He speculates that American reluctance to strengthen the Biological Weapons Convention with enforceable verification and inspection mechanisms reflects a strategic desire to avoid legal scrutiny of these very activities.
Finally, Malone rejects the premise that restricting American access will prevent global proliferation. Citing China’s rapid development of the DeepSeek AI model, he argues that frontier capabilities will inevitably spread across borders, ensuring that adversarial states acquire biological AI tools regardless of U.S. export or access controls. The practical result, he warns, is an asymmetric and more dangerous world where domestic citizens and independent innovators face mounting constraints that hostile foreign governments simply ignore. Ultimately, Malone characterizes Anthropic’s policy not as a genuine biosecurity strategy but as a power grab by an unaccountable nexus of federal agencies, defense contractors, and favored corporations—one that eliminates public oversight without measurably reducing global risk.
